The Sciety syndicate invests MSEK 9.1 in a cardiovascular diagnostic company

The Sciety investor syndicate recently made an investment of MSEK 9.1 in the company Cavis Technologies, which has developed Wirecath®, a patent-pending product for the diagnosis of coronary heart diseases. The new capital will be used to establish sales on the European market.

“Only in Europe, over 1.5 million people die every year from coronary artery disease. The team behind Cavis Technologies has extensive experience in developing pressure wires for the diagnosis of coronary artery disease. Cavis Technologies uses a design different from existing pressure wires, which is expected to provide important clinical benefits” says Andreas Lindblom, CEO of Sciety.

Cardiovascular diseases are the most common cause of death in the world and coronary heart diseases are the leading single cause of death in Europe. Studies have shown that the risk of death can be reduced by over 30% if pressure measurement is used as a diagnostic method. “Despite this fact, the existing pressure wires are used to a low extent, mainly because they are difficult to operate and can give unstable results” says Mats Hilmersson, CEO of Cavis Technologies.

With its pressure wire Wirecath®, Cavis Technologies aims to contribute to more accurate diagnosis for people with coronary artery diseases. With a team having over 15 years of experience in the field, Wirecath® was developed to give cardiologists an easier and faster method that also avoids misdiagnosis.

“We are very satisfied with the collaboration with Sciety. The investment from Sciety and its investor syndicate will be used for our launch and expansion in Europe” says Mats Hilmersson, CEO of Cavis Technologies.

A total of MSEK 9.1 was invested by Sciety’s investor syndicate, of which the investment firm Linc AB and a family office accounted for most of the investment.

Press contact

Andreas Lindblom, CEO of Sciety:, +46 (0) 70 375 73 73.

About Sciety

Sciety is the leading investor syndicate in the Nordics with an exclusive focus on life science and health tech. We combine experience from life science and finance to select promising companies in the industry. Sciety invests own funds in all companies that pass our selection process and offer the network to co-invest on the same terms. The network comprises venture capital firms, family offices and business angels. Sciety’s vision is that innovations in life science reach their full potential.





Documents & Links